These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 21242742

  • 1. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cladribine for multiple sclerosis: review and current status.
    Sipe JC.
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [Abstract] [Full Text] [Related]

  • 11. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA, Roberts RJ, Schlein AL.
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP.
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [Abstract] [Full Text] [Related]

  • 16. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K, Sipe JC.
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 19. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC.
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.